Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
Publication Date Feb 2015
Publisher CurrentPartnering
Product Type Report
Pages 1028
Single User License help $ 3495.00
Site User License help $ 5245.00
Corporate User License help $ 17495.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

"The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.
 
The report provides a detailed understand and analysis of how and why companies enter licensing deals.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
 
This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of licensing dealmaking and business activities.
 
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.
 
Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.
 
Chapter 4 provides a review of the leading licensing deals since 2010. Deals are listed by headline value, signed by bigpharma, most active big pharma, signed by big biotech, most active big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
 
Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2010, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.
                                      
Chapters 6 and 7 provide a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
                   
Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2010 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
          
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2010.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.
 
Report scope
 
Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.      
 
Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
 
Trends in licensing dealmaking in the biopharma industry since 2010
Analysis of licensing deal structure
Case studies of real-life licensing deals
Comprehensive listing of licensing deals since 2010
Access to licensing contract documents
Key financial bnchmarks for headline, upfront, milestone and royalty rates
The leading licensing deals by value since 2010
Most active licensing dealmakers since 2010
The leading licensing partnering resources
In Licensing Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:
 
Company A-Z
Headline value
Therapeutic area
Technology type
 
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. "

"Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in licensing dealmaking

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2010
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals
 
Chapter 3 – Overview of licensing deal structure
 
3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta – Nerviano Medical Sciences – November 2013
3.3.1.b. Case study 2: Sanofi - Pozen – September 2013
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure – January 2014
3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals – September 2013
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena – May 2013
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
 
Chapter 4 – Leading licensing deals
 
4.1. Introduction
4.2. Top licensing deals by value
4.3. Most active licensing dealmakers
4.3.1 Most active licensing dealmakers by therapy
4.3.2. Most active licensing dealmaker by stage of development
4.4. Big pharma licensing deal activity
4.4. Big biotech licensing deal activity
 
Chapter 5 – Licensing deal term benchmarks
 
5.1. Introduction
5.1.2. Licensing headline values
5.1.2.  Licensing upfront payments
5.1.3. Licensing milestone payments
5.1.4. Licensing royalty rates
 
Chapter 6 – Big pharma licensing deals
 
6.1. Introduction
6.2. How to use licensing deals
6.3. Big pharma company licensing agreement listings
Chapter 7 – Big biotech licensing deals
 
7.1. Introduction
7.2. How to use licensing deals
7.3. Big biotech licensing agreement listings
 
Chapter 8 – Licensing contract directory 2010-2014
 
8.1 Introduction
8.2 By company A-Z
8.3. By therapy area
8.4. By stage of development at signing
8.5. By technology area
 
Appendix
 
Appendix 1 – Resources
Appendix 2 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports
 
Additonal appendices – see separate PDF documents:
 
Appendix 1 – Licensing dealmaking - by financial disclosure
Appendix 2 – Licensing dealmaking - by companies A-Z
Appendix 3 – Licensing dealmaking - by stage of development
Appendix 4 – Licensing dealmaking - by therapeutic target
Appendix 5 – Licensing dealmaking - by technology type
 
 
TABLE OF FIGURES
 
Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2010-2014
Figure 5: Licensing deals signed at each phase of development, 2010-2014
Figure 6: Licensing deals by therapy area, 2010-2014
Figure 7: Licensing agreements – what should a contract include?
Figure 8: Components of the licensing deal structure
Figure 9: Top licensing deals by value since 2010 exceeding $1bn
Figure 10: Most active licensing dealmakers 2010-2014
Figure 11: Most active licensing dealmakers 2010-2014 by therapy area
Figure 12: Most active licensing dealmakers 2010-2014 – by stage of development
Figure 13: Big pharma – top 50 – licensing deals 2010 to 2014
Figure 14: Big pharma licensing deal frequency - 2009 to 2014
Figure 15: Big biotech – top 50 – licensing deals 2009 to 2014
Figure 16: Big biotech licensing deal frequency - 2009 to 2014
Figure 17: Licensing deal headline value distribution, US$million – discovery stage
Figure 18: Licensing deal headline value distribution, US$million – preclinical stage
Figure 19: Licensing deal headline value distribution, US$million – phase I stage
Figure 20: Licensing deal headline value distribution, US$million – phase II stage
Figure 21: Licensing deal headline value distribution, US$million – phase III stage
Figure 22: Licensing deal headline value distribution, US$million – regulatory stage
Figure 23: Licensing deal headline value distribution, US$million – marketed stage
Figure 24: Summary median licensing headline value by stage of development, 2010-2014
Figure 25: Licensing deal upfront payment distribution, US$million – discovery stage
Figure 26: Licensing deal upfront payment distribution, US$million – preclinical stage
Figure 27: Licensing deal upfront payment distribution, US$million – phase I stage
Figure 28: Licensing deal upfront payment distribution, US$million – phase II stage
Figure 29: Licensing deal upfront payment distribution, US$million – phase III stage
Figure 30: Licensing deal upfront payment distribution, US$million – regulatory stage
Figure 31: Licensing deal upfront payment distribution, US$million – marketed stage
Figure 32: Summary median licensing upfront payments by stage of development, 2010-2014
Figure 33: Licensing deal milestone distribution, US$million – discovery stage
Figure 34: Licensing deal milestone distribution, US$million – preclinical stage
Figure 35: Licensing deal milestone distribution, US$million – phase I stage
Figure 36: Licensing deal milestone distribution, US$million – phase II stage
Figure 37: Licensing deal milestone distribution, US$million – phase III stage
Figure 38: Licensing deal milestone distribution, US$million – regulatory stage
Figure 39: Licensing deal milestone distribution, US$million – marketed stage
Figure 40: Licensing deals with royalty rates, %
Figure 41: Licensing deal royalty rate distribution, US$million – discovery stage
Figure 42: Licensing deal royalty rate distribution, US$million – preclinical stage
Figure 43: Licensing deal royalty rate distribution, US$million – phase I stage
Figure 44: Licensing deal royalty rate distribution, US$million – phase II stage
Figure 45: Licensing deal royalty rate distribution, US$million – phase III stage
Figure 46: Licensing deal royalty rate distribution, US$million – regulatory stage
Figure 47: Licensing deal royalty rate distribution, US$million – marketed stage
Figure 48: Summary median licensing royalty rate by stage of development, 2010-2014
Figure 49: Online partnering resources
Figure 50: Deal type definitions"

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z